Quantcast
Home > Quotes > NERV
NERV

Minerva Neurosciences, Inc Common Stock (NERV) Quote & Summary Data

$7.59
*  
0.72
8.66%
Get NERV Alerts
*Delayed - data as of Mar. 22, 2019  -  Find a broker to begin trading NERV now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 8.29 / $ 7.57
Share Volume
159,215
50 Day Avg. Daily Volume
135,770
Previous Close
$ 8.31
52 Week High / Low
$ 12.95 / $ 5.80
Market Cap
296,203,325
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
159,215
50 Day Avg. Daily Volume:
135,770

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.29

Trading Range

The current last sale of $7.59 is 30.86% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 8.29 $ 12.95
 Low: $ 7.57 $ 5.80

Company Description (as filed with the SEC)

We are a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system ("CNS"), diseases. Leveraging our scientific insights and clinical experience, we have acquired or in-licensed four development-stage proprietary compounds that we believe have innovative mechanisms of action and therapeutic profiles that potentially address the unmet needs of patients with these diseases. Our product portfolio and potential indications include: roluperidone (also known as MIN-101) for the treatment of negative symptoms in patients with schizophrenia; seltorexant (also known as MIN-202 or JNJ-42847922), which we are co-developing with Janssen Pharmaceutica NV, or Janssen, for the treatment of insomnia disorder and adjunctive treatment of Major Depressive Disorder, or aMDD; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.  ... More ...  



Risk Grade

Where does NERV fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 8.26
Open Date:
Mar. 22, 2019
Close Price:
$ 7.59
Close Date:
Mar. 22, 2019


Consensus Recommendation

Analyst Info